AN AMERICAN BRAIN TUMOR CONSORTIUM (ABTC) PHASE I TRIAL OF ABT-888 (VELIPARIB), TEMOZOLOMIDE (TMZ), AND CONCURRENT RADIOTHERAPY (RT) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): HEMATOLOGIC TOXICITY IS LIMITING.

被引：0
|
作者：
Kleinberg, Lawrence [1 ]
Blakeley, Jaishri [1 ]
Mikkelsen, Tom [2 ]
Stevens, Glenn [3 ]
Ye, Xiaobu [1 ]
Ryu, Sam [2 ]
Desideri, Serena [1 ]
Desai, Bhardwaj [4 ]
Giranda, Vincent [4 ]
Grossman, Stuart [1 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Henry Ford Hosp, Detroit, MI 48202 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Abbott Labs, Chicago, IL USA
来源：
NEURO-ONCOLOGY | 2012年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 36 条
  • [31] Neural Progenitor Cell (NPC) Sparing Radiation Therapy (RT) Plus Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Multiforme (GBM) Associated With Neurocognitive Function But Not Tumor Outcomes: Results of a Prospective Clinical Trial
    Redmond, K. J.
    Ye, X.
    Assadi, R. K.
    McIntyre, R.
    Moore, J.
    Ford, E. C.
    Grossman, S.
    Quinones-Hinojosa, A.
    Kleinberg, L. R.
    Vannorsdall, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S111 - S111
  • [32] PHASE I/II TRIAL OF TEMOZOLOMIDE (TMZ), MOTEXAFIN GADOLINIUM (MGD), AND 60-GY FRACTIONATED RADIATION (RT) FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA: RESULTS OF RTOG 0513 PHASE I DOSE ESCALATION TOXICITY ANALYSIS
    Brachman, David
    Wang, Meihua
    Ashby, Lynn
    Stea, Baldassarre
    Thomas, Theresa
    Mehta, Minesh
    NEURO-ONCOLOGY, 2008, 10 (05) : 889 - 889
  • [33] Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AV Aglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM)
    Wick, Wolfgang
    Cloughesy, Timothy Francis
    Nishikawa, Ryo
    Mason, Warren
    Saran, Frank
    Henriksson, Roger
    Hilton, Magalie
    Kerloeguen, Yannick
    Chinot, Oliver L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] EORTC Study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma-Results of a phase I trial
    Brandes, A. A.
    Stupp, R.
    Hau, P.
    Sleijfer, S.
    Lacombe, D.
    Gorlia, T.
    Yun, H.
    Tosoni, A.
    Mirimanoff, R.
    van den Bent, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM) - CheckMate-548
    Weller, M.
    Vlahovic, G.
    Khasraw, M.
    Brandes, A. A.
    Zwirtes, R.
    Tatsuoka, K.
    Carpentier, A. F.
    Reardon, D. A.
    van den Bent, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] PHASE I STUDY OF ADOPTIVE CELLULAR THERAPY (X-ALT) PLUS TOTAL TUMOR RNA-DENDRITIC CELL VACCINE (TTRNA-DC) plus HEMATOPOIETIC STEM CELLS (HSC) DURING RECOVERY FROM IRRADIATION(RT) WITH (GROUP A) OR WITHOUT (GROUP B) DOSE-INTENSIFIED TEMOZOLOMIDE (DI-TMZ) IN PATIENT (PTS) WITH NEWLY DIAGNOSED DIFFUSE BRAIN STEM GLIOMAS (DIPG) (BRAVO TRIAL)
    Gururangan, Sridharan
    Sayour, Elias
    Flores, Catherine
    Hodik, Marcia
    Mitchell, Duane
    NEURO-ONCOLOGY, 2017, 19 : 9 - 9
1234